The abstract is read at the publisher; the summary is JClub's.
MHT initiation in perimenopausal or recently postmenopausal women with vasomotor symptoms is linked to lower CVD event risk (aHR 0.78, 95% CI 0.62–0.98) in SWAN.
- Why it matters: Most MHT–CVD trials focused on postmenopause and were not designed for women with vasomotor symptoms during the menopause transition, leaving uncertainty about timing and subgroup differences.
- What they did: Using SWAN cohort data (1997–2017) to emulate target trials, investigators compared CVD events among 755 MHT initiators versus noninitiators in CVD-free women reporting hot flashes and/or night sweats.
- The result: The estimated hazard ratio was 0.73 (95% CI 0.58–0.93) when MHT started within 10 or fewer years of menopause onset, but 1.53 (95% CI 0.66–3.52) when started later (interaction P=.02); Black women showed aHR 0.51 (95% CI 0.33–0.81), with interaction P=.007.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.